In an unexpected development, Novartis (NVS) and Amgen (AMGN) filed competing lawsuits over a potentially lucrative relationship to jointly develop and market Aimovig, a new type of migraine treatment that some Wall Street analysts expect will become a multi-billion-dollar market.

The trigger for the dispute was a deal between Sandoz, the generic unit at Novartis, which agreed to do contract manufacturing work for Alder BioPharmaceuticals, which is developing its own migraine treatment. Amgen contended the deal breached its contract with Novartis, while Novartis argued Amgen is using this as a “pretext” to keep Aimovig profits for itself.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy